Spots Global Cancer Trial Database for adalimumab
Every month we try and update this database with for adalimumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers | NCT02516774 | Anaplastic Thyr... | Adalimumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | NCT02092467 | Arthritis, Rheu... | tofacitinib tofacitinib adalimumab etanercept | 50 Years - | Pfizer | |
| Trial of Adalimumab in Progressive Sarcoidosis | NCT00311246 | Sarcoidosis | Adalimumab | 18 Years - 85 Years | University of Chicago | |
| Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease | NCT02499783 | Crohn's Disease | adalimumab placebo | 18 Years - 70 Years | AbbVie | |
| Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis | NCT02893254 | AS | IBI303 Adalimumab | 18 Years - 65 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI | NCT02437253 | Mucopolysacchar... Mucopolysacchar... Mucopolysacchar... | Adalimumab Placebo | 5 Years - | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | NCT04551352 | Cutaneous Melan... Uveal Melanoma Mucosal Melanom... | RO7293583 Tocilizumab Obinutuzumab Adalimumab | 18 Years - | Hoffmann-La Roche | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis | NCT00420927 | Rheumatoid Arth... | adalimumab methotrexate placebo | 18 Years - | Abbott | |
| A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease | NCT04655807 | Crohn Disease | JNJ-64304500 Placebo Adalimumab Ustekinumab | 18 Years - 65 Years | Janssen Research & Development, LLC | |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02163759 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
| Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers | NCT02912247 | Healthy | human recombina... adalimumab | 18 Years - 55 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease | NCT05599347 | Crohn's Disease... Biological Subs... | Azithromycin Pi... Placebo | 18 Years - | Rambam Health Care Campus | |
| Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | NCT03172377 | Crohn Disease i... Crohn Disease | Lengthening ada... | 18 Years - | Radboud University Medical Center | |
| OTIS Autoimmune Diseases in Pregnancy Project | NCT01086059 | Crohn's Disease Rheumatoid Arth... | - | University of California, San Diego | ||
| Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | NCT02092467 | Arthritis, Rheu... | tofacitinib tofacitinib adalimumab etanercept | 50 Years - | Pfizer | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants | NCT05909852 | Adalimumab | ABP 501-HCF ABP 501-LCF | 18 Years - 55 Years | Amgen | |
| Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" | NCT02878161 | Rheumatoid Arth... | methotrexate(ne... infliximab etanercept adalimumab leflunomide (pe... NSAIDs (permitt... Glucocorticoids... | 18 Years - 75 Years | Central South University | |
| A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis | NCT05073315 | Plaque Psoriasi... | Adalimumab ABP 501 | 18 Years - 75 Years | Amgen | |
| Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | NCT02092467 | Arthritis, Rheu... | tofacitinib tofacitinib adalimumab etanercept | 50 Years - | Pfizer | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Trial of Adalimumab in Progressive Sarcoidosis | NCT00311246 | Sarcoidosis | Adalimumab | 18 Years - 85 Years | University of Chicago | |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02171429 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02171429 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
| A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis | NCT05073315 | Plaque Psoriasi... | Adalimumab ABP 501 | 18 Years - 75 Years | Amgen | |
| Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis | NCT02762955 | Psoriasis | BCD-057 Humira® | 18 Years - 75 Years | Biocad | |
| Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis | NCT00420927 | Rheumatoid Arth... | adalimumab methotrexate placebo | 18 Years - | Abbott | |
| Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II) | NCT00595413 | Rheumatoid Arth... | Placebo matched... Atacicept: with... Atacicept Adalimumab | 18 Years - | EMD Serono | |
| Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II) | NCT00595413 | Rheumatoid Arth... | Placebo matched... Atacicept: with... Atacicept Adalimumab | 18 Years - | EMD Serono | |
| Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis | NCT02762955 | Psoriasis | BCD-057 Humira® | 18 Years - 75 Years | Biocad | |
| Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis | NCT01793519 | Rheumatoid Arth... | Etanercept Infliximab Adalimumab Placebo | 18 Years - | Georgetown University | |
| OTIS Autoimmune Diseases in Pregnancy Project | NCT01086059 | Crohn's Disease Rheumatoid Arth... | - | University of California, San Diego | ||
| Repurposing Anti-TNF for Treating Dupuytren's Disease | NCT03180957 | Dupuytren's Dis... | Adalimumab Saline | 18 Years - | University of Oxford | |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02163759 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
| Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | NCT01635764 | Hidradenitis Su... | adalimumab | 18 Years - | AbbVie | |
| Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | NCT01635764 | Hidradenitis Su... | adalimumab | 18 Years - | AbbVie | |
| OTIS Autoimmune Diseases in Pregnancy Project | NCT01086059 | Crohn's Disease Rheumatoid Arth... | - | University of California, San Diego | ||
| Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI | NCT02437253 | Mucopolysacchar... Mucopolysacchar... Mucopolysacchar... | Adalimumab Placebo | 5 Years - | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | |
| Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo | NCT02092389 | Moderate to Sev... | 18 Years - | AbbVie | ||
| Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo | NCT02092389 | Moderate to Sev... | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
